MA26289A1 - Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales - Google Patents

Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales

Info

Publication number
MA26289A1
MA26289A1 MA27664A MA27664A MA26289A1 MA 26289 A1 MA26289 A1 MA 26289A1 MA 27664 A MA27664 A MA 27664A MA 27664 A MA27664 A MA 27664A MA 26289 A1 MA26289 A1 MA 26289A1
Authority
MA
Morocco
Prior art keywords
peroxide
prevention
treatment
low concentration
vaginal infections
Prior art date
Application number
MA27664A
Other languages
English (en)
Inventor
William J Bologna
Howard L Levine
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of MA26289A1 publication Critical patent/MA26289A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA27664A 2001-10-29 2004-04-29 Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales MA26289A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33068301P 2001-10-29 2001-10-29
US10/278,910 US7709026B2 (en) 2001-10-29 2002-10-24 Low concentration of peroxide for treating or preventing vaginal infections

Publications (1)

Publication Number Publication Date
MA26289A1 true MA26289A1 (fr) 2004-09-01

Family

ID=26959335

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27664A MA26289A1 (fr) 2001-10-29 2004-04-29 Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales

Country Status (31)

Country Link
US (1) US7709026B2 (fr)
EP (1) EP1441769B1 (fr)
JP (2) JP5153049B2 (fr)
KR (1) KR101009146B1 (fr)
CN (1) CN1578676A (fr)
AR (1) AR037047A1 (fr)
AT (1) ATE297222T1 (fr)
AU (1) AU2002346897B2 (fr)
BR (1) BR0213584A (fr)
CA (1) CA2465133C (fr)
DE (1) DE60204584T2 (fr)
DK (1) DK1441769T3 (fr)
ES (1) ES2243772T3 (fr)
HK (1) HK1063290A1 (fr)
HR (1) HRP20040480B1 (fr)
HU (1) HU229487B1 (fr)
IL (2) IL161512A0 (fr)
MA (1) MA26289A1 (fr)
ME (1) MEP34608A (fr)
MX (1) MXPA04003977A (fr)
MY (1) MY137791A (fr)
NO (1) NO20042199L (fr)
NZ (1) NZ532294A (fr)
PE (1) PE20030492A1 (fr)
PL (2) PL216746B1 (fr)
PT (1) PT1441769E (fr)
RS (1) RS51154B (fr)
RU (1) RU2329829C2 (fr)
SI (1) SI1441769T1 (fr)
WO (1) WO2003037382A1 (fr)
ZA (1) ZA200402943B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
CH697081A5 (de) * 2002-01-22 2008-04-30 Andreas F Dr Schaub Zusammensetzung für die Unterstützung der Geburt eines menschlichen Föten.
US20040126369A1 (en) * 2002-12-30 2004-07-01 Richard Payne Delivery of peroxide-generating enzymes to the vaginal tract
DE10328942A1 (de) * 2003-06-27 2005-01-27 Lts Lohmann Therapie-Systeme Ag Transmukosale Darreichungsformen mit verminderter Schleimhautirritation
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
US20050276865A1 (en) * 2004-05-20 2005-12-15 Servet Buyuktimkin Peroxide compounds for the prevention and treatment of sexual dysfunction in humans
DE102004054552A1 (de) * 2004-11-11 2006-05-18 Hcb Happy Child Birth Holding Ag Neue Zusammensetzung zur Erleichterung der Humangeburt
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US20120074014A1 (en) * 2010-09-27 2012-03-29 Lutran Industries, Inc. Product typically based on salt of peroxymonosulfuric acid and suitable for medicinal usage, and associated product fabrication
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
US9895311B2 (en) 2014-09-25 2018-02-20 Pharmiva Ab Foam-forming compositions and methods for delivering an active to a body cavity
US20180280340A1 (en) * 2017-03-30 2018-10-04 Konstantin Zubovskiy Method of treating and preventing infections
AU2018272880B2 (en) 2017-05-23 2024-02-29 Pharmiva Ab Foam-forming compositions for delivering an active to a body cavity
CN113164384A (zh) * 2018-10-26 2021-07-23 维拉莫有限公司 黏膜粘附性凝胶组合物
US11850303B2 (en) * 2020-10-27 2023-12-26 Uqora, Inc. Gel and a suppository and methods to provide the gel and suppository

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
NL88710C (fr) * 1954-01-25
NL230864A (fr) * 1957-08-27
US4127515A (en) * 1974-10-21 1978-11-28 Colgate-Palmolive Company Waxing sponge
US4607101A (en) * 1981-08-27 1986-08-19 Jaye-Boern Laboratories, Inc. Method of treating acne vulgaris with a composition containing carbamide peroxide
WO1985002092A1 (fr) * 1983-11-14 1985-05-23 Bio-Mimetics Inc. Compositions bio-adhesives et procedes de traitement a l'aide de celles-ci
US4657935A (en) * 1985-07-22 1987-04-14 Carlos Teplicki Real acne control (RAC)
US4997625A (en) * 1985-08-07 1991-03-05 Simon Gilbert I Chemical sterilization
US4923677A (en) * 1985-08-07 1990-05-08 Roy T. Witkin Chemical sterilization
US4670256A (en) * 1985-09-23 1987-06-02 V. Valhalla Corp. Vaginal conditioning for sexual activity
US4781923A (en) * 1987-07-20 1988-11-01 Pellico Michael A Antiseptic gels
US5536743A (en) * 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US6017521A (en) * 1989-10-31 2000-01-25 Columbia Laboratories, Inc. Use of polycarboxylic acid polymers to treat vaginal infections
US5376006A (en) * 1990-03-22 1994-12-27 Ultradent Products, Inc. Dental bleaching compositions and methods for bleaching teeth surfaces
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5340836A (en) * 1991-02-19 1994-08-23 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
US5573765A (en) * 1991-02-19 1996-11-12 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5571533A (en) * 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
US5667817A (en) * 1992-03-20 1997-09-16 Alcide Corporation Method and composition for prevention and treatment of female lower genital tract microbial infections
US5898037A (en) * 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5489435A (en) * 1993-07-06 1996-02-06 Ratcliff; Perry A. Composition for treatment of abnormal conditions of the epithelium of bodily orifices
US6200557B1 (en) * 1993-07-06 2001-03-13 Perry A. Ratcliff Method of treating HIV by a topical composition
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
UA39965C2 (uk) * 1993-12-03 2001-07-16 Лайфор Леборетріз Лтд Вірусоцидний, бактерицидний та руйнуючий сперматозоїди вагінальний засіб і вагінальний супозиторій ( варіанти )
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
US5741525A (en) * 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
PT869772E (pt) * 1995-12-27 2002-03-28 Janssen Pharmaceutica Nv Forma galenica solida bioadesiva
US5778886A (en) * 1996-02-27 1998-07-14 Shihata; Alfred Vaginal compositions combining a spermicidal agent and a peroxygen compound
US5819742A (en) * 1996-11-06 1998-10-13 Family Health International Vaginal device for preventing conception or the transmission of sexually transmitted diseases, or both
US6093394A (en) * 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
US5843998A (en) * 1997-06-30 1998-12-01 Song; Jin Skin blemish treatment
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6117859A (en) * 1997-11-04 2000-09-12 The Research Foundation Of State University Of New York Method of relieving chronic inflammation by using 5-alkylsulfonylsalicylanilides
CN1306444A (zh) 1998-06-19 2001-08-01 奥西比奥公司 具有抗感染和避孕性能的医学装置
US6277363B1 (en) * 1998-09-21 2001-08-21 Vortech, Inc. Method and composition for treating chlamydia infection
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
JP2003512310A (ja) 1999-10-22 2003-04-02 リーフ−フラウプ イーエイチエフ バイオ−ゲルズ ファーマシューティカルス インコーポレイテッド 粘膜上皮潰瘍および／または糜爛の治療用製薬組成物
US6200551B1 (en) * 2000-01-27 2001-03-13 Susan Ann Morgan Treatment for dry mouth employing carbamide peroxide
US6235314B1 (en) * 2000-08-08 2001-05-22 Sarfaraz K. Niazi Analgesic, anti-inflammatory and skeletal muscle relaxant compositions
ATE356798T1 (de) * 2000-10-02 2007-04-15 Univ New York State Res Found Naphthylsalicylanilide als antimikrobielle und entzündungshemmende mittel
US20030211173A1 (en) 2002-05-08 2003-11-13 Veach Tom C. Lubrication composition
EP1654012B1 (fr) * 2003-08-06 2013-04-24 Basf Se Materiau gonflable dans l'eau comprenant des particules de polymeres gonflables dans l'eau, revetues
US20090156672A1 (en) * 2007-12-17 2009-06-18 Northwestern University Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities

Also Published As

Publication number Publication date
RS51154B (sr) 2010-10-31
AU2002346897B2 (en) 2008-04-17
EP1441769B1 (fr) 2005-06-08
NZ532294A (en) 2006-12-22
PE20030492A1 (es) 2003-06-16
PL369725A1 (en) 2005-05-02
MY137791A (en) 2009-03-31
JP2005510505A (ja) 2005-04-21
DE60204584D1 (de) 2005-07-14
NO20042199L (no) 2004-05-26
DK1441769T3 (da) 2005-09-12
ATE297222T1 (de) 2005-06-15
CA2465133C (fr) 2012-03-06
PT1441769E (pt) 2005-08-31
EP1441769A1 (fr) 2004-08-04
KR20050056903A (ko) 2005-06-16
HK1063290A1 (en) 2004-12-24
US20030091644A1 (en) 2003-05-15
DE60204584T2 (de) 2006-03-16
SI1441769T1 (sl) 2005-12-31
CN1578676A (zh) 2005-02-09
MEP34608A (en) 2011-02-10
KR101009146B1 (ko) 2011-01-18
PL402550A1 (pl) 2013-08-05
JP2010248232A (ja) 2010-11-04
PL216746B1 (pl) 2014-05-30
US7709026B2 (en) 2010-05-04
CA2465133A1 (fr) 2003-05-08
AR037047A1 (es) 2004-10-20
IL161512A0 (en) 2004-09-27
WO2003037382A1 (fr) 2003-05-08
ES2243772T3 (es) 2005-12-01
RS36604A (en) 2006-12-15
HRP20040480B1 (en) 2007-11-30
HU229487B1 (en) 2014-01-28
ZA200402943B (en) 2005-03-30
BR0213584A (pt) 2004-08-24
HUP0401672A3 (en) 2008-04-28
RU2329829C2 (ru) 2008-07-27
HUP0401672A2 (hu) 2005-07-28
RU2004116312A (ru) 2005-04-10
MXPA04003977A (es) 2004-07-08
HRP20040480A2 (en) 2004-10-31
JP5153049B2 (ja) 2013-02-27
IL161512A (en) 2009-07-20

Similar Documents

Publication Publication Date Title
MA26289A1 (fr) Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales
MA25775A1 (fr) Combinaison des bacteries d'acide lactique et son utilisation pour la prevention et/ou le traitement des infections et des etats inflammatoires.
MA25823A1 (fr) Compositions pour le traitement de l'eau.
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
MA26207A1 (fr) Compositions de traitement de l'eau.
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
MA27374A1 (fr) Ester de 2'-c-methyl-3'-o-l-valine et de ribofuranosyl cytidine pour le traitement des infections des flaviviridae
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
DZ1877A1 (fr) Forme posologiques d'azithromycine pour le traitement d'infection microbiennes.
SE0102315D0 (sv) Compounds
ATE305306T1 (de) Reboxetin zur behandlung von peripheren neuropathien
MA26889A1 (fr) Composition pharmaceutique pour le traitement de la douleur aigue chronique et/ ou neuropathique et des migraines
ATE510562T1 (de) Anti-ailim antikörper zur behandlung von crohn's
ID26043A (id) Turunan-turunan 1,3,5-triazina tertrisubstitusi untuk pengobatan infeksi-infeksi hiv
FR14C0010I2 (fr) Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
MA26896A1 (fr) Utilisation de compositions d'antibiotiques azalides pour le traitement ou la prevention d'une infection par des bacteries ou protozoaires chez des mammiferes
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
MA25501A1 (fr) Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
FR2831446B1 (fr) Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire